Placebo-controlled clinical trial in cancer
GlycaNova is currently conducting a pioneering, placebo-controlled clinical trial in which late-stage colorectal cancer patients are receiving GlycaNova’s LentinexHP in addition to chemotherapy.
GlycaNova is an innovative Norwegian biotechnology company focused on the modulation of the immune system using proprietary 1,3 beta-glucans derived from medicinal mushrooms.
GlycaNova’s beta-glucans are scientifically proven to be significantly more bioavailable and bioactive than other beta-glucans owing to GlycaNova’s unique manufacturing process which preserves the beta-glucans’ triple helix three-dimensional structure, thereby optimising absorption and biological activity.
In addition to the current clinical trial in cancer, GlycaNova has developed clinically proven consumer healthcare products for immune system support and problematic skin conditions and also focuses on animal health.